Director/PDMR Shareholding

RNS Number : 6925A

MaxCyte, Inc.

01 October 2020

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director Dealings

Maryland, USA - 1 October 2020 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company,  announces that J. Stark Thompson, Non-Executive Chairman of the Company, has exercised options over 25,000 shares of common stock of 0.1 pence of the Company ("Common Stock") ("Exercise"). In order to fund a near term personal tax liability, the 25,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have today been sold by Dr Thompson at a price of £3.55 pence per Common Stock ("Sale"). Dr Thompson has no current intention of making further sales of MaxCyte shares.

Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains unchanged at a total of 110,918 Common Stock representing a total of 0.14% of the issued share capital of the Company. Dr Thompson holds a further 241,333   options over Common Stock.

Total voting rights

The New Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the above will be 77,305,169 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,405,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	J. Stark Thompson
2	Reason for the notification
a)	Position/status	Non-Executive Chairman and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1 pence each
b)	Identification Code	US57777K1060
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£3.55	25,000
e)	Aggregated information - Aggregated volume - Price	N/A (Single Transaction)
f)	Date of the transaction	1.10.20
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit        www.maxcyte.com   .   

For further information, please contact: MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer [phone] Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden [phone] Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith [phone] Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji  [phone] [e-mail]

 

END

 

 

DSHEAENEDEAEEAA